Molecular mechanisms of programmed death-ligand 1 (PD-L1) mRNA expression and roles of apoptosis and biomarkers are poorly understood in epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma patients. Thirty-three patients with recurrent postoperative EGFR-mutant lung adenocarcinoma (exon 19 deletion in 16, L858R in 15, G719C in 2 patients) treated with gefitinib were studied. PD-L1 mRNA expression of formalin-fixed paraffin-embedded paratumoral and intratumoral tissues was quantified by PCR. Correlations of PD-L1 mRNA expression with BIM, p53 upregulated modular of apoptosis (PUMA), human epidermal growth factor receptor 2 (HER2), mesenchymal-epithelial transition (MET), EGFR, and vascular endothelial growth factor A (VEGFA) were determined. Eleven of the 33 patients (33.3%) and 14/33 patients (42.4%) expressed intratumoral and paratumoral PD-L1 mRNA, respectively. Patients with intratumoral PD-L1 mRNA expression had significantly higher BIM and lower VEGFA expression compared with paratumoral PD-L1 mRNA patients (P=0.049, P=0.009). PD-L1 mRNA expression was not associated with the expression of PUMA, HER2, EGFR and MET but was positively correlated with BIM expression (r=0.41, P=0.017) and inversely correlated with VEGFA expression (r=−0.33, P=0.043). Patients with intratumoral PD-L1 mRNA expression had significantly shorter median progression-free survival (PFS) after gefitinib therapy compared with no PD-L1 expression (255 vs. 732 days, respectively; P=0.032). Thus, PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma was associated with BIM and VEGFA mRNA expression and with shorter PFS after gefitinib therapy.
Activating mutations in epidermal growth factor receptor (EGFR) were reported to be potential targets for the treatment of non-small cell lung cancer (NSCLC) (1,2). EGFR mutation frequency was reported to vary by population type; for example, in North America and Western Europe, approximately 5–10% of adenocarcinoma patients contain mutations, whereas approximately 60–70% of non-smokers in East Asia have EGFR mutations (3,4). EGFR tyrosine kinase inhibitors (EGFR-TKIs) including gefitinib, erlotinib, and afatinib have demonstrated marked radiographic and clinical improvement in patients with EGFR mutations and are recommended for the treatment of EGFR-mutant NSCLC (5,6). A longer progression-free survival (PFS) was reported in NSCLC patients with such mutations who were treated with an EGFR-TKI as a first-line therapy compared with those receiving platinum-based chemotherapy (7–11). The expression of PD-L1, BCL2L11 (BIM), p53 upregulated modular of apoptosis (PUMA), human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor A (VEGFA), EGFR and mesenchymal-epithelial transition (MET) were reported to be prognostic factors for patients with EGFR mutations receiving EGFR-TKI therapy (12–18).
Programmed death 1 (PD-1) is a co-inhibitory receptor expressed on activated T and B cells and is involved in tumor immune escape (19–21). The PD-1 ligand, termed programmed death-ligand 1 (PD-L1), has been reported to be overexpressed in many cancers (22). Recent clinical trials have shown promising efficacy for PD-L1 and PD-1 antibody blockade in NSCLC (23–25). A recent study reported that PD-L1 was expressed in 19.6–65.3% of NSCLC patients (26–30) and that EGFR mutation status was associated with PD-L1 expression as assessed by immunohistochemistry (IHC) (31, 32). Chen et al (33) reported three pathways of EGFR activation: i) EGF simulation; ii) EGFR-19 del; and iii) EGFR-L858R mutation, which induced PD-L1 expression. Therefore, constitutive oncogenic pathway activation may upregulate PD-L1 expression. Azuma et al (32) reported that high PD-L1 expression was associated with the presence of EGFR mutations in surgically resected NSCLC indicating it may be an independent negative prognostic factor.
Several studies have reported an association between PD-L1 and apoptotic activity and angiogenesis in addition to other prognostic factors of EGFR-TKI (34,35). For this reason, HER2, EGFR and MET genes were selected as prognostic markers of EGFR-TKI, VEGFA was selected as an angiogenic marker, and BIM and PUMA were selected as apoptotic markers. This study investigated the association between PD-L1 mRNA expression and other prognostic factors for EGFR-TKI therapy, including BIM, PUMA, HER2, VEGFA, EGFR and MET in lung tissue from patients with EGFR-mutant NSCLC.
Patients and methodsClinical samples
Samples from 33 patients with recurrent postoperative EGFR-mutant lung adenocarcinoma (exon 19 deletion in 16, L858R in 15, G719C in 2 patients) treated with gefitinib between January 2008 and January 2016 were obtained. The inclusion criteria were: i) patients with advanced and postoperative recurrent NSCLC; ii) patients with an EGFR mutation (Del 19, L858R mutation, and minor mutation); iii) patients treated with gefitinib; iv) patients aged <80 years; and v) either male or female patients. The exclusion criteria were: i) patients with complications or a history of serious lung disorder; ii) pregnant women, women who may possibly be pregnant, women who hope to be pregnant, lactating women; and iii) men who declined contraception.
mRNA expression of PD-L1, BIM, PUMA, HER2, VEGFA, EGFR and MET were investigated by the real-time PCR analysis of 33 formalin-fixed paraffin-embedded (FFPE) slides of intratumoral and paratumoral lung tissue surgical samples.
mRNA extraction from intratumoral and paratumoral tissues
Total RNA including miRNA was extracted from FFPE sections of intratumoral and paratumoral lung tissues using a miRNeasy FFPE kit (Qiagen KK, Tokyo, Japan) according to the manufacturer's protocol. Paratumoral tissues were defined as normal lung cells including inflammatory cells, and/or mesenchymal cells in the same section with a 1–2 cm distance from the tumor edge.
Detection of PD-L1, BIM, PUMA, HER2, VEGFA, EGFR and MET
Total RNA was stored at −80°C until use. cDNA was synthesized using PrimeScript RT MasterMix (Perfect Real-Time; Takara Bio, Inc., Otsu, Japan). Quantitative real-time PCR was performed using a Thermal Cycler Dice Real-Time System TP800 (Takara Bio, Inc.), using SYBR Premix Ex Taq II (Tli RNaseH Plus; Takara Bio, Inc.). Each PCR reaction used Perfect Real Time primers (Takara Bio, Inc.) as follows: PD-L1 forward, 5′-CGTCTCCTCCAAATGTGTATCA-3′ and reverse, 5′-TGGTAATTCTGGGAGCCATC-3′; BIM-EL forward, 5′-GAGCCACAAGGTAATCCTGAA-3′ and reverse, 5′-ATACCCACTGGAGGATCGAG-3′; BIM-L forward, 5′-GACAGAGCCACAAGACAGGA-3′ and reverse, 5′-GGAAGCCATTGCACTGAGATA-3′; BIM-S forward, 5′-AGACAGAGCCACAAGCTTCC-3′ and reverse, 5′-TGCATAGTAAGCGTTAAACTCG-3′; PUMA forward, 5′-GACGACCTCAACGCACAGTA-3′ and reverse, 5′-GAGATTGTACAGGACCCTCCA-3′; HER2 forward, 5′-GGAAACCTGGAACTCACCTACCTG-3′ and reverse, 5′-AGTGGGACCTGCCTCACTTG-3′; VEGFA forward, 5′-TCACAGGTACAGGGATGAGGACAC-3′ and reverse, 5′-CAAAGCACAGCAATGTCCTGAAG-3′; EGFR forward, 5′-GTGGCGGGACATAGTCAGCA-3′ and reverse, 5′-CCCATTGGGACAGCTTGGA-3′; MET forward, 5′-TCCCATCAACAGGACTACACACTT-3′ and reverse, 5′-GCTGCAGGTATAGGCAGTGACAA-3; and GAPDH forward, 5′-GCACCGTCAAGGCTGAGAAC-3′ and reverse, 5′-TGGTGAAGACGCCAGTGGA-3′.
Quantification of PD-L1, BIM, PUMA, HER2, VEGFA, EGFR and MET expression
The targets were obtained from the same mRNA preparations. The relative expression of PD-L1, BIM, PUMA, HER2, VEGFR, EGFR and MET in mRNA isolated from tissue sections of intratumoral and paratumoral lung tissues, normalized to the reference gene (GAPDH), were calculated using the KCL22 or H2228 cell line for calibration (35–37). PD-L1 negative was defined as no detection of PD-L1 mRNA in this study.
Validation between PD-L1 mRNA levels and IHC
We confirmed the validity between PD-L1 mRNA levels and PD-L1 expression by IHC. PD-L1 IHC was performed using an automated IHC assay (Dako; Agilent Technologies, Inc., Santa Clara, CA, USA) with rabbit anti-human PD-L1 antibody (clone 28-8, cat. no. ab205921; Epitomics; Abcam, Burlingame, CA, USA). Tumor PD-L1 protein expression was confirmed when staining of the tumor-cell membrane (at any intensity) was observed at a prespecified expression in a section that included at least 100 tumor cells that could be evaluated.
Clinical outcomes
We retrospectively analyzed the clinical characteristics, response rate, and disease control rate for gefitinib in patients with and without PD-L1. We then estimated the PFS and overall survival (OS). OS was defined as the interval from the date of diagnosis until death from any cause. The PFS of patients treated with gefitinib was assessed from the date of induction of gefitinib therapy until the first sign of disease progression, as determined by computed tomographic or magnetic resonance imaging, according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
Statistical analysis
Statistical analyses were performed using SPSS software for Windows, version 12.0 (SPSS Inc., Tokyo, Japan). Differences in the relative expression of PD-L1, BIM, PUMA, HER2, VEGFA, EGFR and MET between patients with and without PD-L1 expression were compared with the Wilcoxon rank-sum test. Survival curves were plotted using the Kaplan-Meier method, and the log-rank test was used for statistical analysis. A P-value <0.05 indicated a statistically significant difference.
We used univariate analysis and multivariate Cox regression analysis to identify factors associated with a shorter PFS and OS. The investigated prognostic factors were age, sex (male vs. female), performance status (PS; 2 vs. 1 vs. 0), brain metastasis (yes vs. no), bone metastasis (yes vs. no), pulmonary metastasis (yes vs. no), pleura metastasis (yes vs. no), liver metastasis (yes vs. no), lymph node metastasis (yes vs. no), EGFR mutation [major mutations (L858R and exon 19 deletion) vs. minor mutations (other mutations)], smoking history [pack(s)-year], and intratumoral PD-L1 expression (yes vs. no).
This single-center study was conducted at Toho University Omori Medical Center (Tokyo, Japan) and was approved by its Human Genome/Gene Analysis Research Ethics Committee (authorization no. 27128).
ResultsPD-L1 mRNA expression in EGFR-positive NSCLC
We analyzed PD-L1 mRNA expression in 33 patients with EGFR mutation-positive NSCLC patients who were treated with gefitinib. The patient characteristics are presented in Table I. Intratumoral PD-L1 mRNA expression was noted in 11 out of 33 patients (33.3%), and paratumoral expression was noted in 14 out of 33 patients (42.4%) (Table II). Six patients had both intratumoral and paratumoral PD-L1 expression. There was no significant difference in the relative expression of PD-L1 mRNA between intratumoral and paratumoral tissues (P=0.056) (Fig. 1).
Validation between PD-L1 mRNA levels and IHC results
We confirmed the validity between the PD-L1 mRNA levels and PD-L1 expression by IHC. There was a significant correlation between PD-L1 mRNA levels and PD-L1 IHC expression (r=0.44, P=0.015) (Fig. 2).
Association of PD-L1 expression with BIM, PUMA, HER2, VEGFR, EGFR and MET expression
Patients with intratumoral PD-L1 mRNA expression had significantly higher BIM expression and significantly lower VEGFA expression compared with those without PD-L1 expression (P=0.049 and P=0.009, respectively) (Table III). The expression of PUMA, HER2, EGFR, and MET was not associated with PD-L1 mRNA expression status. Paratumoral PD-L1 mRNA expression was not associated with the expression of BIM, PUMA, HER2, VEGFA, or EGFR (Table III).
Correlations of PD-L1 mRNA expression with BIM and VEGFA expression
We assessed the correlations of intratumoral PD-L1 mRNA expression with BIM and VEGFA mRNA expression. PD-L1 mRNA expression was positively correlated with BIM expression (r=0.41, P=0.017) (Fig. 3) and inversely correlated with VEGFA expression (r= −0.33, P=0.043) (Fig. 4). However, PD-L1 mRNA expression was not correlated with the expression of HER2, EGFR, MET, and PUMA expression (Fig. 5).
Clinical response and survival
There were no significant differences in the response rate or disease control rate between patients with (n=11) or without (n=22) intratumoral PD-L1 expression (Table IV). Patients with intratumoral PD-L1 mRNA expression had a significantly shorter median PFS after gefitinib therapy compared with those without PD-L1 expression (255 vs. 732 days, respectively; P=0.032) (Fig. 6). However, the median OS did not significantly differ between these groups (1,291 vs. 1,511 days, P=0.24) (Fig. 7).
Multivariate Cox regression analysis revealed that intratumoral PD-L1 expression was the most important independent indicator of a shorter PFS (hazard ratio, 2.953; 95% confidence interval, 1.270–6.868; P=0.012) (Table V). However, intratumoral PD-L1 expression was not an indicator of a shorter OS.
Discussion
We investigated the association between PD-L1 mRNA expression and prognostic factors associated with EGFR-TKI therapy, including BIM, PUMA, HER2, VEGFA, EGFR and MET in the lung tissues of patients with EGFR-mutant NSCLC. PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma was associated with BIM and VEGFA mRNA expression and with a shorter PFS after gefitinib therapy. To the best of our knowledge, this is the first study of the association of BIM and VEGFA mRNA expression in human NSCLC clinical samples.
EGFR activation induced PD-L1 expression, indicating that this constitutive oncogenic pathway activation may upregulate PD-L1 (33). IHC analysis revealed that PD-L1 was positive in 53.6–58.8% of tumor specimens in patients with EGFR-mutant NSCLC (38–40). In the present study, intratumoral PD-L1 mRNA expression was noted in 11 out of 33 patients (33.3%). This lower ratio may be explained by the degradation of mRNA in the specimens used in this study. Future studies should examine the correlation between PD-L1 mRNA expression and PD-L1 protein expression deternined by IHC.
BIM is a proapoptotic protein of the B-cell CLL/lymphoma 2 (Bcl-2) family of proteins and is a key modulator of apoptosis induced by EGFR-TKI (41). It has been reported that BIM upregulation is related to the expression of PD-L1 by tumor-reactive CD8+ T cells in patients with malignant melanoma (42). In the present study, patients with detectable PD-L1 mRNA expression had significantly higher BIM expression (P=0.049), and PD-L1 mRNA expression was positively correlated with BIM expression. Recently, Dronca et al (34) reported that BIM, regulated by PD-1 and PD-L1, was crucial for T-cell activation and apoptosis, especially in effector CD8+ T cells from melanoma patients, and that T-cell BIM levels reflected the patient response to anti-PD-1 cancer therapy. Future studies should examine the association between PD-L1 and BIM.
Although VEGF pathway activation is most commonly associated with increased angiogenesis, recent studies reported that increased angiogenesis promoted an immunosuppressive tumor microenvironment (43–45). Other studies suggested that VEGF inhibition increased the number of tumor-infiltrating lymphocytes (46). Joseph et al reported that PD-L1 expression assessed by IHC was inversely correlated with the expression of VEGFA, VEGFR1, and VEGFR2 in clear cell renal carcinoma (35). In the present study, VEGFA expression was significantly lower in patients with intratumoral PD-L1 mRNA expression compared with patients lacking PD-L1 mRNA expression (P=0.009). In addition, the relative PD-L1 mRNA expression was inversely correlated with VEGFA expression (r= −0.33, P=0.043). These findings indicated that tumors with increased VEGF expression have decreased immune infiltration and therefore, there is less adaptive pressure to express PD-L1.
High IHC staining of PD-L1 was associated with a poor prognosis in several human malignancies, indicating that high intratumoral PD-L1 expression may drive tumor recurrence by preventing antitumor immunity (47,48). PD-L1-positive patients treated with EGFR-TKI had a faster disease progression compared with PD-L1-negative patients (49,50). Data from the present study revealed that as PD-L1 expression increased, VEGFA expression decreased leading to the suppression of angiogenesis, tumor growth and metastasis, which consequently shortened the PFS of EGFR-TKI. In EGFR mutation-positive NSCLC, BIM reflects the expression of PD-L1 because it is a downstream signal of PD-L1; therefore, future clinical applications are expected. PD-L1 expression has been reported to change after EGFR-TKI treatment (51). Han et al (51) reported that intratumoral PD-L1 IHC expression was markedly increased in 38.9% of patients after gefitinib treatment. Since samples were obtained and used before treatment in the present study, there appears to be no correlation between the expression of PD-L1 and EGFR, MET, and HER2. Our future study will investigate the relationship between PD-L1 expression and EGFR, MET and HER2 after EGFR-TKI resistance. Furthermore, it was suggested that PD-L1 expression was also related to BIM-mediated apoptosis and VEGFA-mediated angiogenesis in EGFR-mutated lung cancer.
This study had some limitations. First, it was a retrospective single-center study with a small sample size. We revealed differences in clinical outcome according to PD-L1 expression; however, the number of patients enrolled was too small to consider the association of PD-L1 expression and PFS. Furthermore, the OS was not different between patients with and without PD-L1 expression. Thus, a large-scale multicenter study is required to confirm the validity of our results. Second, there is a possibility of the influence of mRNA deterioration in the specimens used in this study. In addition, since we used a cell line as a control and samples to produce the standard curve, we cannot assess/confirm that the clinical samples were of sufficient high quality to produce meaningful results in the present study.
In conclusion, PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma was associated with BIM and VEGFA mRNA expression and with a shorter PFS after gefitinib therapy. The present results should help treatment planning for patients with EGFR-mutant NSCLC.
Acknowledgements
We thank Yoshihisa Otsuka of SRL Inc. (Tokyo, Japan), Yusuke Hashizawa and Akimitsu Iwama of Astra Zeneca Inc. (Tokyo Japan) and Yusuke Hozumi of Ono Pharmaceutical Co., Ltd. (Tokyo Japan). We are also grateful to David Kipler and N.A.I. Inc. for the review of the language of this study.
Funding
The present study was supported by JSPS KAKENHI (grant nos. JP15K09195 and JP2642140) and by a Research Promotion Grant from Toho University Graduate School of Medicine (no. 16-3, to KI).
Availability of data and materials
The datasets used during the present study are available from the corresponding author upon reasonable request.
Author's contributions
KI, AK, TMi and SH conceived and designed the study. KK, HK, TY and YN performed the experiments. KI and AK wrote the paper. TMa, HO, GS, KS, SS, YT, NT, AI and SH reviewed and edited the manuscript. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Ethics approval and consent to participate
This single-center study was conducted at Toho University Omori Medical Center (Tokyo, Japan) and was approved by its Human Genome/Gene Analysis Research Ethics Committee (authorization no. 27128).
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
National Cancer Institute Common Terminology Criteria
ReferencesPaezJGJännePALeeJCTracySGreulichHGabrielSHermanPKayeFJLindemanNBoggonTJEGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapyScience30414971500200410.1126/science.109931415118125LynchTJBellDWSordellaRGurubhagavatulaSOkimotoRABranniganBWHarrisPLHaserlatSMSupkoJGHaluskaFGActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med35021292139200410.1056/NEJMoa04093815118073TanDSMokTSRebbeckTRCancer genomics: Diversity and disparity across ethnicity and geographyJ Clin Oncol3491101201610.1200/JCO.2015.62.009626578615TanDSYomSSTsaoMSPassHIKellyKPeledNYungRCWistubaIIYatabeYUngerMThe International Association for the Study of Lung Cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer: Status in 2016J Thorac Oncol11946963201610.1016/j.jtho.2016.05.00827229180MastersGATeminSAzzoliCGGiacconeGBakerSJrBrahmerJREllisPMGajraARackearNSchillerJHSystemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline UpdateJ Clin Oncol3334883515201510.1200/JCO.2015.62.1342263243675019421KuanFCKuoLTChenMCYangCTShiCSTengDLeeKDOverall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: A systematic review and meta-analysisBr J Cancer11315191528201510.1038/bjc.2015.356264610594815883MokTSWuYLThongprasertSYangCHChuDTSaijoNSunpaweravongPHanBMargonoBIchinoseYGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med361947957200910.1056/NEJMoa081069919692680MaemondoMInoueAKobayashiKSugawaraSOizumiSIsobeHGemmaAHaradaMYoshizawaHKinoshitaINorth-East Japan Study Group: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med36223802388201010.1056/NEJMoa090953020573926ZhouCWuYLChenGFengJLiuXQWangCZhangSWangJZhouSRenSErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 studyLancet Oncol12735742201110.1016/S1470-2045(11)70184-X21783417YangJCWuYLSchulerMSebastianMPopatSYamamotoNZhouCHuCPO'ByrneKFengJAfatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trialsLancet Oncol16141151201510.1016/S1470-2045(14)71173-825589191MitsudomiTMoritaSYatabeYNegoroSOkamotoITsurutaniJSetoTSatouchiMTadaHHirashimaTWest Japan Oncology Group: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trialLancet Oncol11121128201010.1016/S1470-2045(09)70364-X20022809BeanGRGanesanYTDongYTakedaSLiuHChanPMHuangYChodoshLAZambettiGPHsiehJJPUMA and BIM are required for oncogene inactivation-induced apoptosisSci Signal6ra20201310.1126/scisignal.2003483235323343753585IsobeKKakimotoAMikamiTKaburakiKKobayashiHYoshizawaTMakinoTOtsukaHSanoGOSuginoKAssociation of BIM deletion polymorphism and BIM-γ RNA expression in NSCLC with EGFR mutationCancer Genomics Proteomics13475482201610.21873/cgp.20010278070705219921CostaCMolinaMADrozdowskyjAGiménez-CapitánABertran-AlamilloJKarachaliouNGervaisRMassutiBWeiJMoranTThe impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trialClin Cancer Res2020012010201410.1158/1078-0432.CCR-13-223324493829GarofaloMRomanoGDi LevaGNuovoGJeonYJNgankeuASunJLovatFAlderHCondorelliGEGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancersNat Med187482201110.1038/nm.2577221576813467100NaumovGNNilssonMBCasconeTBriggsAStraumeOAkslenLALifshitsEByersLAXuLWuHKCombined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistanceClin Cancer Res1534843494200910.1158/1078-0432.CCR-08-2904194478652893040HirschFRVarella-GarciaMCappuzzoFPredictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancerOncogene28Suppl 1S32S37200910.1038/onc.2009.19919680294RhoJKChoiYJLeeJKRyooBYNaIIYangSHLeeSSKimCHYooYDLeeJCThe role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitorsMol Cancer Res717361743200910.1158/1541-7786.MCR-08-050419808904AgataYKawasakiANishimuraHIshidaYTsubataTYagitaHHonjoTExpression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytesInt Immunol8765772199610.1093/intimm/8.5.7658671665NishimuraHHonjoTPD-1: An inhibitory immunoreceptor involved in peripheral toleranceTrends Immunol22265268200110.1016/S1471-4906(01)01888-911323285WatanabeNGavrieliMSedyJRYangJFallarinoFLoftinSKHurchlaMAZimmermanNSimJZangXBTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1Nat Immunol4670679200310.1038/ni94412796776KeirMEButteMJFreemanGJSharpeAHPD-1 and its ligands in tolerance and immunityAnnu Rev Immunol26677704200810.1146/annurev.immunol.26.021607.09033118173375BrahmerJReckampKLBaasPCrinòLEberhardtWEPoddubskayaEAntoniaSPluzanskiAVokesEEHolgadoENivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN Engl J Med373123135201510.1056/NEJMoa1504627260284074681400BorghaeiHPaz-AresLHornLSpigelDRSteinsMReadyNEChowLQVokesEEFelipEHolgadoENivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med37316271639201510.1056/NEJMoa1507643264124565705936HerbstRSBaasPKimDWFelipEPérez-GraciaJLHanJYMolinaJKimJHArvisCDAhnMJPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trialLancet38715401550201610.1016/S0140-6736(15)01281-726712084AfreenSDermimeSThe immunoinhibitory B7-H1 molecule as a potential target in cancer: Killing many birds with one stoneHematol Oncol Stem Cell Ther7117201410.1016/j.hemonc.2013.09.00524398144BolandJMKwonEDHarringtonSMWampflerJATangHYangPAubryMCTumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lungClin Lung Cancer14157163201310.1016/j.cllc.2012.05.00622868219KonishiJYamazakiKAzumaMKinoshitaIDosaka-AkitaHNishimuraMB7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expressionClin Cancer Res1050945100200410.1158/1078-0432.CCR-04-042815297412ChenYYWangLBZhuHLLiXYZhuYPYinYLLüFZWangZLQuJMRelationship between programmed death-ligand 1 and clinicopathological characteristics in non-small cell lung cancer patientsChin Med Sci J28147151201310.1016/S1001-9294(13)60040-124074616MuCYHuangJAChenYChenCZhangXGHigh expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturationMed Oncol28682688201110.1007/s12032-010-9515-220373055AkbayEAKoyamaSCarreteroJAltabefATchaichaJHChristensenCLMikseORCherniackADBeauchampEMPughTJActivation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumorsCancer Discov313551363201310.1158/2159-8290.CD-13-031024078774AzumaKOtaKKawaharaAHattoriSIwamaEHaradaTMatsumotoKTakayamaKTakamoriSKageMAssociation of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancerAnn Oncol2519351940201410.1093/annonc/mdu24225009014ChenNFangWZhanJHongSTangYKangSZhangYHeXZhouTQinTUpregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: Implication for optional immune targeted therapy for NSCLC patients with EGFR mutationJ Thorac Oncol10910923201510.1097/JTO.000000000000050025658629DroncaRSLiuXHarringtonSMChenLCaoSKottschadeLAMcWilliamsRRBlockMSNevalaWKThompsonMAT cell Bim levels reflect responses to anti-PD-1 cancer therapyJCI Insight11201610.1172/jci.insight.86014JosephRWParasramkaMEckel-PassowJESerieDWuKJiangLKalariKThompsonRHHoHuu TCastleEPInverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinomaCancer Immunol Res1378385201310.1158/2326-6066.CIR-13-0042247781304322777VandesompeleJDe PreterKPattynFPoppeBVan RoyNDe PaepeASpelemanFAccurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genesGenome Biol3RESEARCH0034200210.1186/gb-2002-3-7-research003412184808126239WongMLMedranoJFReal-time PCR for mRNA quantitationBiotechniques397585200510.2144/05391RV0116060372D'InceccoAAndreozziMLudoviniVRossiECapodannoALandiLTibaldiCMinutiGSalviniJCoppiEPD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patientsBr J Cancer11295102201510.1038/bjc.2014.55525349974TangYFangWZhangYHongSKangSYanYChenNZhanJHeXQinTThe association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIsOncotarget61420914219201510.18632/oncotarget.3694258950314546461LinCChenXLiMLiuJQiXYangWZhangHCaiZDaiYOuyangXProgrammed death-ligand 1 expression predicts tyrosine kinase inhibitor response and better prognosis in a cohort of patients with epidermal growth factor receptor mutation-positive lung adenocarcinomaClin Lung Cancer16e25e35201510.1016/j.cllc.2015.02.00225801750GongYSomwarRPolitiKBalakMChmieleckiJJiangXPaoWInduction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomasPLoS Med4e294200710.1371/journal.pmed.0040294179274462001209GibbonsRMLiuXPulkoVHarringtonSMKrcoCJKwonEDDongHB7-H1 limits the entry of effector CD8(+) T cells to the memory pool by upregulating BimOncoimmunology110611073201210.4161/onci.20850231702543494620HuangYGoelSDudaDGFukumuraDJainRKVascular normalization as an emerging strategy to enhance cancer immunotherapyCancer Res7329432948201310.1158/1538-7445.AM2013-LB-344234404263655127WeiJWuAKongLYWangYFullerGFoktIMelilloGPriebeWHeimbergerABHypoxia potentiates glioma-mediated immunosuppressionPLoS One6e16195201110.1371/journal.pone.0016195212837553024401OttPAHodiFSBuchbinderEIInhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: An overview of rationale, preclinical evidence, and initial clinical dataFront Oncol5202201510.3389/fonc.2015.00202264422144585112HuangYYuanJRighiEKamounWSAncukiewiczMNezivarJSantosuossoMMartinJDMartinMRVianelloFVascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapyProc Natl Acad Sci USA1091756117566201210.1073/pnas.1215397109230456833491458ZouWChenLInhibitory B7-family molecules in the tumour microenvironmentNat Rev Immunol8467477200810.1038/nri232618500231ChenJJiangCCJinLZhangXDRegulation of PD-L1: A novel role of pro-survival signalling in cancerAnn Oncol27409416201610.1093/annonc/mdv61526681673OkitaRMaedaAShimizuKNojimaYSaishoSNakataMPD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancerCancer Immunol Immunother66865876201710.1007/s00262-017-1986-y28341875ShimojiMShimizuSSatoKSudaKKobayashiYTomizawaKTakemotoTMitsudomiTClinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)Lung Cancer986975201610.1016/j.lungcan.2016.04.02127393509HanJJKimDWKohJKeamBKimTMJeonYKLeeSHChungDHHeoDSChange in PD-L1 expression after acquiring resistance to gefitinib in EGFR-mutant non-small-cell lung cancerClin Lung Cancer17263270.e262201610.1016/j.cllc.2015.11.00626707383
The relative expression of PD-L1 is similar between paratumoral (285.6±631.3; mean ± SD) and intratumoral (67.2±631.3; mean ± SD) tissues. *P=0.056. Error bars indicate the SD.
PD-L1 mRNA expression is positively correlated with PD-L1 IHC expression. r=0.44, P=0.015. PD-L1, programmed death-ligand 1; IHC, immunohistochemistry.
PD-L1 mRNA expression is positively correlated with BIM expression. r=0.41, P=0.017. PD-L1, programmed death-ligand 1; BIM, BCL2L11.
PD-L1 mRNA expression is inversely correlated with VEGFA expression. r=−0.33, P=0.043. PD-L1, programmed death-ligand 1; VEGFA, vascular endothelial growth factor A.
PD-L1 mRNA expression is not correlated with HER2 (r=−0.11, P=0.56), EGFR (r=−0.67, P=0.22), MET (r= −0.44, P=0.81), and PUMA (r=0.06, P=0.93) expression. PD-L1, programmed death-ligand 1; HER2, human epidermal growth factor receptor 2; EGFR, epidermal growth factor receptor; MET, mesenchymal-epithelial transition; PUMA, p53 upregulated modular of apoptosis.
Kaplan-Meier curves for PFS. The median PFS was significantly shorter for patients with detectable intratumoral PD-L1 mRNA expression after gefitinib therapy compared with those lacking PD-L1 mRNA expression (255 vs. 732 days, respectively). *P=0.032. PFS, progression-free survival; PD-L1, programmed death-ligand 1.
Kaplan-Meier curves for OS. There was no significant difference in the median OS between the groups (1291 vs. 1511 days). P=0.24. OS, overall survival.